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Abstract 
Background: Assessing the quality of medicines in low-middle income countries (LMICs) relies primarily on human 
inspection and screening technologies, where available. Field studies and surveys have frequently utilized screening 
tests to analyse medicines sampled at the point of care, such as health care facilities and medicine outlets, to provide 
a snap shot of medicine quality in a specific geographical area. This review presents an overview of the screening tests 
typically employed in surveys to assess anti-malarial medicine quality, summarizes the analytical methods used, how 
findings have been reported and proposes a reporting template for future studies.
Methods: A systematic search of the peer-reviewed and grey literature available in the public domain (including 
national and multi-national medicine quality surveys) covering the period 1990–2016 was undertaken. Studies were 
included if they had used screening techniques to assess the quality of anti-malarial medicines. As no standardized set 
of guidelines for the methodology and reporting of medicine quality surveys exist, the included studies were assessed 
for their standard against a newly proposed list of criteria.
Results: The titles and abstracts of 4621 records were screened and only 39 were found to meet the eligibility criteria. 
These 39 studies utilized visual inspection, disintegration, colorimetry and Thin Layer Chromatography (TLC) either as 
components of the Global Pharma Health Fund (GPHF)  MiniLab® or as individual tests. Overall, 30/39 studies reported 
employing confirmatory testing described in international pharmacopeia to verify the quality of anti-malarials post 
assessment by a screening test. The authors assigned scores for the 23 criteria for the standard of reporting of each study.
Conclusions: There is considerable heterogeneity in study design and inconsistency in reporting of field surveys of 
medicine quality. A lack of standardization in the design and reporting of studies of medicine quality increases the risk 
of bias and error, impacting on the generalizability and reliability of study results. The criteria proposed for reporting 
on the standard of studies in this review can be used in conjunction with existing medicine quality survey guidelines 
as a checklist for designing and reporting findings of studies. The review protocol has been registered with PROSPERO 
(CRD42015026782).
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Background
Malaria remains a major public health concern in low 
and middle income countries (LMICs), although, in 
recent years, there has been an overall decline in malaria 
incidence due to application of improved strategies 
for prevention, control and treatment [1]. The advent 
of artemisinin-based treatment has contributed to the 
reduction in disease transmission, with 79 out of 88 
malaria-endemic countries having adopted artemisinin-
based combination therapy (ACT) as first-line treatment 
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for uncomplicated Plasmodium falciparum malaria by 
2015 [2]. Assuring the quality of ACTs and other anti-
malarials used to counter malaria is paramount in ensur-
ing that the success of malaria prevention and control 
strategies is maintained. Yet, the reported finding that a 
third of anti-malarial medicines from malaria endemic 
countries failed chemical content analysis is a source of 
substantial concern, potentially threatening progress in 
control [3]. At the patient level, poor quality anti-malar-
ials may result in treatment failure, leading to prolonged 
or severe illness and even death, as sub-therapeutic med-
icine concentrations increase the risk of recrudescence of 
malaria infection [4]. At the provider level this increases 
burden on already limited resources and undermines 
confidence in health providers [5]. From a public health 
perspective medicines with low stated active pharmaceu-
tical ingredients (SAPI) or low bioavailability may select 
for drug resistant parasites [6]. An association between 
the quality of artemisinin-based medicines and drug 
resistance has been postulated but not as yet proven [7].
In-country, medicine quality can most readily be 
assessed at two stages in the supply chain; at point of 
entry and point of care. Firstly, anti-malarials permitted to 
enter the official supply chain in LMICs should, ideally be 
restricted to those produced by World Health Organiza-
tion (WHO) prequalified manufacturers that have attained 
accreditation for good manufacturing practice (GMP) [8]. 
However, this is seldom the case, and often National Medi-
cines Regulatory Authorities (NMRAs) will permit non-
WHO prequalified medicines, assuming they have met 
GMP standards. Some countries may also have anti-malar-
ials on the market that may not have been registered with 
the NMRA. Secondly, wholesalers have to obtain authori-
zation from the NMRA before they can distribute medi-
cines [9], and the products they import should satisfy the 
national regulatory requirements for obtaining pre-mar-
keting authorization. Finally, subsequent medicine batches 
may undergo routine lot-quality sampling [10] and testing 
by a NMRA at the point of entry in some countries. How-
ever, the source of anti-malarials often varies, ranging from 
international wholesalers to direct donations from external 
organizations or medicine manufacturers [11]. Donated 
medicines can sometimes bypass these initial checks, mak-
ing verification of their quality more challenging. Indeed, 
studies have shown that some donated medicines are more 
likely to be close to their manufacturer expiry date or have 
exceeded their shelf-life [12].
Point of entry sampling and analysis requires substan-
tial initial and recurrent investment in resources, exper-
tise and equipment, all of which are rarely affordable or 
available to LMICs on a routine basis. Thus, NMRAs 
most frequently rely on post marketing surveillance 
through periodic medicine quality sampling surveys 
at the point of care, using screening technologies [13]. 
Even so, the proportion of NMRAs in LMICs with reg-
ular access to screening technologies is not known. To 
this end, several new screening technologies have been 
developed in recent years. This review aims to present an 
overview of the screening tests used to assess medicine 
quality at point of care. It will also focus on the screening 
technologies and survey methods that have been used to 
assess medicine quality in field surveys, and the standard 
of reporting. A template for future reporting of studies is 
also proposed and is used to score the anti-malarial med-
icine quality studies included in this review.
Principles of assessing medicine quality
Tests for medicine quality are based on assessment of 
identity, chemical assay, disintegration and dissolution 
(bioavailability). These four core ‘principles’ provide the 
basis for medicine quality analytical technologies, which 
can also be further categorized as screening and con-
firmatory functions in a medicine quality surveillance 
system (MQSS) [14]. Fundamentally, an ideal test should 
be capable of detecting both counterfeit (or falsified) and 
substandard medicines (see Fig. 1 for definitions) through 
verification of the chemical content in terms of the stated 
active pharmaceutical ingredients (SAPIs) [15–17].
Surveillance systems for medicine quality in LMICs 
employ screening techniques and devices as the first 
stage for medicine quality analysis. Some of these tech-
nologies (listed in Table 1 together with their description, 
cost (where available) and role in the MQSS) are port-
able, simple to use and relatively inexpensive, making 
Fig. 1 Definitions of poor quality medicines. *As of January 2017, the WHO member state mechanism has recommended that the use of “substand-
ard/spurious/falsely-labelled/falsified/counterfeit medical products” should be replaced with “substandard and falsified medical products”
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them suitable for screening large volumes of medicines. 
Nevertheless, they may only provide an indication of 
medicine quality, necessitating subsequent confirmation 
and quantification of the SAPI with more specific quanti-
tative techniques found in medicine quality control labo-
ratories, following methods described in international 
pharmacopeia.
Laboratory methods such as high performance liquid 
chromatography (HPLC) and mass spectrometry (MS) 
are needed to confirm the chemical content of a medi-
cine in terms of its SAPI and are regarded as the ‘gold 
standard’ technique for medicine quality analysis. HPLC 
detects the SAPI and its amount is determined from the 
calibration curve measuring the peaks achieved using 
increasing known amounts of the reference standard. 
Thereafter, an analyst will assess if a medicine falls within 
tolerance limits for content in accordance with interna-
tional pharmacopeia. Dissolution tests to determine the 
bioavailability of the medicine require specialist appara-
tus and can only be carried out when authorized phar-
macopeia monographs exist. These techniques incur a 
high capital and maintenance cost and require specific 
laboratory infrastructure including highly skilled indi-
viduals for effective operation. Not all LMICs have the 
human and capital resources to thus maintain a fully 
functional MQSS. To enable medicines quality control 
laboratories to conform to international standards, the 
WHO operates a prequalification programme providing 
accreditation through ISO (ISO/IEC17025) certification. 
To achieve accreditation a medicines quality control lab-
oratory must satisfy requirements for ‘Good practices for 
pharmaceutical quality control laboratories’, which will 
provide confidence in the services they provide [18].
In LMICs medicine quality screening technologies 
(Table 2) thus play a pivotal role in the surveillance of the 
quality of anti-malarials due to limited technical capac-
ity. Analytical equipment such as HPLC and dissolution 
testing apparatus may be absent or only available at the 
national reference laboratory and even then, all pharma-
copeia methods may not be possible to set up due to inter-
rupted power supply, prohibitive costs involved (HPLC 
columns, reference standards etc.) and the requirement 
for highly skilled chemists to carry out the analysis. In 
contrast, portable screening techniques, require no elec-
tricity or advanced expertise to perform, can be used for 
testing large numbers of medicines in field surveys, and 
identifying suspect samples which are then subjected to 
comprehensive content analysis using confirmatory tests. 
Screening tests can thus be used as part of a national 
MQSS, most suitable for use in peripheral laboratories, 
border posts and other points of entry into a country.
Guidelines for conducting medicine quality studies 
and surveys
Currently, there are no universally agreed guidelines 
on the study design and reporting of medicine quality 
Table 1 Tests for assessing the quality of a medicine
a Denotes relative cost of the technology; inexpensive—less than $10,000 (*), moderate—$10,000–$100,000 (**), very expensive—greater than $100,000 (***) [24]
Test dimensions Description Medicine analytical technology Role in a MQSS Costa 
Identity Verifies identity of SAPI Visual examination of packaging
Counterfeit detection device (CD3)
RAMAN spectroscopy (hand-held device)
Specialized mass spectrometry (MS) techniques










Assay Detection and quantitation of SAPI Semi-quantitative thin layer chromatography (TLC) 
(GPHF  MiniLab®)
High performance liquid chromatography (HPLC) 








Disintegration Determines that a tablet or capsule will disintegrate GPHF  MiniLab® Screening *
Dissolution Proxy measure of the bioavailability of a medicine 
(extent to which medicine will dissolve in the 
body)
Dissolution apparatus Confirmatory **
Table 2 Descriptions for screening and confirmatory tests
Type of test Description Examples of tests
Screening Basic tests for quality based 
on, but not restricted to, 
chromatographic and 
spectrometric tech-
niques with the addition 
of visual inspection




Confirmatory Methods listed in pharma-
copeia, that can only be 
conducted in a labora-
tory by trained personnel 
and the results from 
which are quantifiable
HPLC; Dissolution; MS; 
LC–MS
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studies or surveys, although there are at least three pri-
mary sources of information and guidance available. The 
United States Pharmacopeia (USP) operates a Promoting 
the Quality of Medicines Program providing technical 
and logistical support to LMICs. In 2006, USP published 
guidelines for sampling and analysing medicines for their 
quality [19]. In the same year Global Health Pharma Fund 
(GPHF) also produced a manual of testing procedures for 
the quality of medicines, to accompany the  MiniLab®. 
The manual is updated on an annual basis to include 
testing guidelines for new medicines and modified pro-
cedures for existing medicines [20]. Lastly, in 2009, a 
proposal for a checklist for the sampling of medicines 
for medicine quality studies and surveys called MED-
QUARG, was published [21].
Methods
A systematic review of the published literature between 
1990 and 2016 was undertaken in January 2016 and 
updated in October 2016. PubMed, Web of Science and 
Google Scholar were searched using predefined search 
terms as described in the protocol in Table 3. This review 
was carried out in accordance with PRISMA guidelines 
[22] and the protocol has been registered with PROS-
PERO, (ref: CRD42015026782). Articles were imported 
into Endnote and duplicates removed. Further searches 
were conducted using ancestral and forward citation of 
two prominent anti-malarial medicine quality reviews as 
well as searches of the grey literature using the World-
wide Antimalarial Resistance Network (WWARN) medi-
cine quality surveyor [3, 23]. Where accessible, published 
national medicine quality surveys and reports were also 
obtained.
Titles, abstracts and executive summaries were 
assessed by the first author (ML) of this manuscript for 
their relevance (summarized in Table  3). Studies that 
reported utilizing screening tests for anti-malarials were 
included for full text review. Studies and reports pub-
lished in English and French were included.
An assessment of the quality of reporting of the eli-
gible reports and studies was undertaken to examine 
the rigour of study design and sources of potential bias 
in findings. The authors applied criteria adapted from a 
previously published review [25], published procedures 
of individual tests, USP Medicine Quality and Informa-
tion Program Guidelines [19], MEDQUARG guidelines 
[21], and the GRADE guidelines (quality of evidence 
and strength of recommendations for diagnostic tests 
or strategies) [26, 27]. The process gave rise to a final list 
of 23 criteria of reporting quality (listed in Fig. 2); these 
items assessed how studies report aspects of field collec-
tion of medicine samples, storage, method of medicine 
Table 3 Summary of review search criteria
b Kovacs et al. [24] have reviewed all medicine quality screening technologies in use and categorized them by cost and portability. Their scoring matrix has been used 
as an exclusion criterion with an LMIC score of less than 4 representing those technologies that are less feasible for use in LMICs due to their lack of portability and 
high cost
Databases 1. PubMed
2. Web of Science
3. Google Scholar
Other sources 1. Nayyar et al. [23]
2. Tabanero et al. [3]
3. USP DQI country reports [85]
4. WWARN anti-malarial medicine quality surveyor [86]
Key search terms Medicine OR drug quality AND survey OR screening
Screening: AND poor quality OR counterfeit OR substandard (medicine OR drug)
Detection: AND poor quality OR counterfeit OR substandard (medicine OR drug)
Eligibility criteria
 Dates 1990–2016
 Language English, French
 Location Central, South and South East Asia, Sub-Saharan Africa, Central and South America, Pacific Islands
 Article type Scientific publications in international peer-reviewed journals and grey literature (reports and surveys)
 Types of studies Field surveys in which anti-malarial medicines were assessed for quality, using a screening technique
 Screening technique and outcome 1. Screening techniques: tests based on but not restricted to chromatographic and spectrometric techniques 
with the addition of visual inspection or visual inspection alone
2. Outcome measure (medicine quality)
 Exclusion criteria 1. Reviews/Commentaries/Conference Papers/Letters
2. High specification, non-portable technologies (as defined by Kovacs et al. [24] with LMIC score <4b)
3. Feasibility studies
4. Non-anti-malarial medicine assessed for quality alone
5. Only results of either screening or confirmatory tests presented when both undertaken
 Search dates January 2016, updated October 2016
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quality assessment categorized as level I (visual inspec-
tion), level II (screening tests) and level III (confirma-
tory tests), medicine quality analysis and interpretation, 
dissemination, study limitations and bias. Data extracted 
from eligible studies were organized under the following 
headings; study details (year of collection and location), 
medicine sampling and storage, screening tests, con-
firmatory tests, classification of quality, statistical tests, 
limitations, bias and dissemination. Studies included at 
this stage were full text versions and were independently 
assessed by two of the authors (ML and FEK). Discrep-
ancies were clarified and a final list of reconciled studies 
was produced for inclusion. Two separate tables were 
compiled, one listing studies that used a screening test 
only and studies using both screening plus confirma-
tory tests (see Additional files 1, 2). The scoring criteria 
was applied to both sets of studies (screening alone and 
screening plus confirmatory).
Results
The titles and abstracts of 4621 records were screened 
(after duplicates were removed) and 146 were identified 
based on the eligibility criteria (Fig. 3). Studies excluded 
at this stage were predominantly not related to medicine 
quality and included pharmacovigilance (drug safety) 
studies, diagnostic testing for illicit or banned sub-
stances and several clinical trials of new drug targets. The 
remaining 146 records were subjected to full text review 
against the exclusion criteria. This resulted in 39 articles 
that assessed the quality of anti-malarial medicines using 
a screening test which were subsequently reviewed and 
summarized.
Types of studies
Of the 39 included studies and surveys in this review, 
the vast majority (36/39) were peer-reviewed articles 
published in international journals and three were non-
peer-reviewed publications, which comprised two multi-
country surveys (one conducted by the WHO [28] and 
the other by USP [29]) and a national medicine quality 
survey undertaken by the Malaria Control and Pharmacy 
and Poisons Board for Kenya [30]. The latter was the only 
national Ministry of Health agency survey report that 
met the eligibility criteria to be included in this review. 
Of the 39 included studies, 33 were conducted in South 
East Asia and Sub-Saharan Africa, with the remainder 
undertaken in Afghanistan [5], India [31, 32] Guyana and 
Suriname [33], the Amazon Basin [34] and Papua New 
Guinea [35]. Of the 25 studies from Africa, 15 were con-
ducted in Nigeria and Ghana [28, 36–48]. The remainder 
comprized the aforementioned national medicine qual-
ity survey conducted by a Ministry of Health agency in 
Kenya [30] and two multi-country surveys, conducted 
by USP in Madagascar, Senegal and Uganda [29] and 
the WHO in Kenya, Nigeria, Ghana, Ethiopia, Tanzania 
and Cameroon [28]. Multi-country studies accounted for 
12/39 (30.8%) [28, 29, 33, 34, 42–46, 49–51] that met the 
inclusion criteria.
A variety of outlets from all levels of the distribution 
chain were represented among the studies. Most of the 
studies sampled at point-of-care; public health facilities 
(government funded hospitals and clinics), private sector 
pharmacies and the informal sector (markets stalls, itin-
erant sellers and grocery shops). Three studies sampled 
from the highest level of the distribution chain such as 
wholesalers and central medical stores (in addition to 
hospitals, pharmacies etc.) [30, 52, 53]. In the included 
studies, a broad range of anti-malarial medicines were 
sampled and analysed for quality.
Tests used for screening medicine quality
The WHO medicine testing guidelines recommends 
combining qualitative and quantitative approaches to 
analysis, to establish the identity, content and disintegra-
tion of a medicine [54]. Qualitative tests include visual 
inspection, colorimetric tests and tablet or capsule dis-
integration. Visual inspection involves assessment of the 
medicine packaging, patient information leaflet and the 
medicine itself. Misspellings, absence of an expiry date 
or batch number and obvious signs of deterioration of 
the product indicate a poor quality medicine [55]. How-
ever, for a full appraisal, prior knowledge of the authentic 
manufacturers packaging is required, which would not be 
routinely available to a patient or a medicine outlet pro-
prietor. Colorimetric tests are identity tests that involve 
a simple colour reaction to verify presence of the SAPI. 
The disintegration test requires the tablet/capsule to dis-
integrate in water heated to 37 °C, within 30 min. If this 
does not occur, it could indicate a poor quality product. 
Thin layer chromatography (TLC) is an example of semi-
quantitative testing [56]. The combination of the steps of 
visual inspection followed by disintegration testing give 
an assessment of deficiencies related to medicine solubil-
ity and availability. The third step of carrying out a colour 
reaction indicates if the SAPI is present before employ-
ing a TLC run for verification of whether the quantities 
of medicine claimed on the label are in the sample.
All of these tests are incorporated in the GPHF 
 MiniLab® which is capable of testing around 80 WHO 
essential medicines (including anti-malarials) and is 
reportedly available in over 90 countries worldwide, 
and often used in LMICs as an integral component of a 
MQSS [57]. TLC is an identity/content test that provides 
a semi-quantitative analysis in which a spot of the medi-
cine under investigation is solubilized in an appropriate 
solvent and applied to a TLC plate and should migrate at 
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Fig. 2 Criteria for assessing the standard of reporting of medicine quality surveys. Adapted from a previously published review, published pro-
cedures of individual tests, MEDQUARG guidelines, USP Medicine Quality and Information Program Guidelines and consideration of the GRADE 
guidelines (quality of evidence and strength of recommendations for diagnostic tests or strategies)
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the same rate as that for the similarly solubilized refer-
ence standard (equivalent to 80 and 100% of the SAPI). 
If the spot formed by the medicine is obviously different 
to the reference spots in colour and size this may indi-
cate a poor quality sample. Indeed the sample spot must 
be at least similar to the lower working reference spot 
representing ‘80%’ to be considered as a ‘pass’ accord-
ing to  MiniLab® guidelines [20]. Thus colorimetric tests 
and TLC constitute a subjective evaluation of medicine 
quality, dependent on the visual acuity of the technician 
conducting the test.
Other tests intended for use in field surveys for detect-
ing poor quality medicines include paper test cards, the 
Raman handheld device and near-infrared spectrometers 
(NIR), all of which are in various stages of development 
[58, 59]. These tests employ spectroscopy or separation 
techniques and are based on the principle of identity, 
verifying the SAPI in a medicine sample. The Raman 
Fig. 3 Literature review search strategy
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and NIR spectrometer devices scan medicine samples 
through the blister pack. They identify a unique spec-
tral ‘fingerprint’ allowing comparison of a suspect sam-
ple with a genuine medicine which requires access to a 
library of spectra for each individual brand of medicine 
on the market. Thus far, only the  TruScan® handheld 
Raman device has demonstrated the ability to detected 
counterfeits the field [60]. In contrast to the Raman 
device, NIR can distinguish whether the excipients in a 
medicine sample are in the correct proportions, sug-
gesting that the medicine is falsified, but it cannot detect 
substandard medicines [61]. Separation techniques 
employing paper-based chromatography allow testing of 
multiple SAPIs on a single piece of card (known as mul-
tiplexing) [62]. They are inexpensive and simple to use 
but have a low accuracy in terms of quantification of the 
SAPI. Field experience of the Raman, NIR and paper tests 
cards to date is restricted to a limited number of studies 
[46, 60, 63]. The cost of the Raman device remains a lim-
iting factor to more widespread use. Nevertheless, a new, 
comparatively low cost and portable prototype version of 
NIR has recently demonstrated a promising capability in 
detecting falsified samples of ACTs and artemisinin mon-
otherapies [64].
Amongst the 39 eligible field surveys of medicine qual-
ity published between 1990 and 2016, there was lim-
ited variation in the screening techniques that had been 
employed. All studies had utilized visual inspection, dis-
integration, colorimetry and TLC either as components 
of the GPHF  MiniLab® or as individual tests. Overall, 
4/39 (10%) studies were limited to visual inspection alone 
[33, 36, 49, 65]. In 7/39 (18%) studies, more than one 
screening test was employed; of which, five compared the 
 MiniLab® with Raman Spectrometry and/or near infra-
red (NIR) [43–46, 66]. The CD-3 device, which analyses 
medicine packaging was reported in just one study [67] 
and another study employed MVHimagePCv8.exe Color 
Software which measures colour intensity of samples 
subjected to the colorimetric Fast Red TR test, using dig-
ital imagery [47].
Standard of reporting
In addition to the variation between studies in the out-
lets from which medicines were collected for analysis 
and the screening techniques employed, there was con-
siderable variation in how results were reported. None of 
the included studies met all 23 criteria of the standard of 
reporting (see Fig. 4). Scores ranged from 17/23 (74%) as 
the highest [67] and 2/23 (9%) [47] as the lowest. Stud-
ies published before 2006 [10/39, (26%)] scored an aver-
age of 6.9 compared to 8.5 for those published after 2006. 
This marginal improvement may have been in response 
to the publication of the  MiniLab® manual (instructions 
on testing procedures) and USP guidelines in 2006. The 
number of studies satisfying each of the quality of report-
ing assessment criteria are presented in Fig. 4.
Medicine storage and collection
Improper storage conditions have been suggested as a 
possible risk factor for deteriorating medicine quality 
over time, which if drugs are not stored adequately prior 
to analysis, could cause the proportion of poor quality 
medicines to be overestimated (misclassification bias) 
[68]. Nevertheless, reporting of storage conditions after 
collection was generally poor; only 4/39 (10%) studies 
stated maintaining appropriate storage conditions during 
transit from the outlet to the laboratory and less than half 
(15/39 (39%)) reported storage conditions in the labora-
tory prior to analysis [30, 65, 67, 69]. The scale of the sur-
veys and number of samples analysed varied substantially 
between studies. USP guidelines for medicine sampling 
state that a minimum of 30 dosage units per location be 
collected, sufficient to carry out testing for identity and 
content of SAPI and dissolution [19]. Yet overall, 10/39 
(26%) studies based their findings on a sample size of less 
than 30 [32, 35, 37–41, 47, 49, 52].
Visual inspection/packaging analysis
Visual assessment of medicine packaging and the tab-
let or capsule is an inexpensive approach but requires 
the original packaging from the manufacturer for accu-
rate comparison. The GPHF  MiniLab® manual provides 
guidelines to standardize visual inspection. In this review 
9/39 (23%) studies did not state undertaking a visual 
assessment [31, 32, 46, 47, 52, 70–72]. Of those studies 
that did undertake visual inspection, 12 mentioned refer-
ring to  MiniLab® guidelines [5, 28, 29, 34, 43, 45, 48, 
66, 73–76]. Only 4/39 (10%) studies carried out packag-
ing analysis (all from SE Asia) and reported comparison 
with a sample of the genuine packaging obtained from 
the medicine manufacturer [39, 65, 67, 77]. One study, 
explicitly stated contacting manufacturers for the original 
packaging without response [69].
Description of laboratory procedures (screening tests)
References standards are pure chemical compounds 
obtained from chemical manufacturing companies and 
are used by pharmacopeia such as USP as a basis for their 
official monographs for analysts to adopt. This review 
found that 15/39 (39%) studies stated using reference 
standards in the analytical process and reported on the 
source of the standard [30, 35, 38–42, 45, 46, 49, 65, 67, 
76, 78, 79]. Of the 35/39 (89.7%) studies (excluding those 
that conducted visual inspection alone), 10/35 (29%) did 
not mention the source of the screening tests (and rea-
gents), but simply named the device they were utilizing; 
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 MiniLab® or a Raman handheld device [28–32, 42, 45, 48, 
51, 72].
Interpretation results from visual inspection, colori-
metric and TLC tests are subjective and dependent on 
the visual acuity of the operator. A second operator to 
independently verify test results would enhance the valid-
ity of a study by minimizing the risk of operator error in 
results interpretation, particularly for the semi-quantita-
tive TLC test in which there is a greater risk of misclassi-
fication bias. Overall, 31 studies used TLC, but only three 
reported using a second operator to verify results [38, 69, 
75]. For 8/39 (21%) studies using visual inspection and/or 
colorimetry, a second operator would be unnecessary as 
results are more definitive in comparison to TLC.
USP guidelines for medicine quality testing using the 
 MiniLab®, state that any samples of doubtful quality or 
‘failed’ samples, as well as 5–10% of passed samples must 
be retested using disintegration and TLC techniques 
[19]. Devices such as the Raman handheld and CD3 are 
new additions to the market and at the time of the stud-
ies in which they undertaken, there was no mention of 
the need for test repetition. Of the studies that employed 
disintegration and TLC, just 7/30 (23%) reported repeat 
testing of samples [30, 43–45, 73, 75, 76]. Moreover, just 
5/39 (13%) studies reported having blinded the opera-
tors to results from visual/packaging analysis or from 
screening tests, thus increasing the risk of performance 
(observer) bias [50, 51, 67, 70, 77]. In total, 7/39 (18%) 
studies discussed using a rudimentary strategy for select-
ing medicines from their initial sample to be analysed 
further by confirmatory tests (often to verify doubtful 
quality or failure of samples) [28–30, 67, 69, 74, 76]. The 
remaining studies either did not use confirmatory tests or 
the screening tests did not highlight any failing samples.
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22. Study limitations and bias
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6. Use of a reference package
5. Guidelines for visual inspection used
4. Visual and physical inspection
3. Sample size > 30 (units of a drug)
2. Laboratory conditions prior to analysis
1. Storage conditions during transportation
Number of studies
Fig. 4 Number of medicine quality survey reports satisfying each reporting quality criterion
Page 10 of 14Lalani et al. Malar J  (2017) 16:197 
Confirmatory testing using pharmacopeia methods
In total, 9/39 (23%) studies did not employ confirmatory 
tests, hence their results simply provide an indication of 
medicine quality [31, 43–48, 66, 78]. A fairly wide range 
of confirmatory tests were applied in the remaining 30/39 
(77%) studies, although three studies did not specify the 
test that had been carried out [30, 34, 75]. Tests assessing 
both the physical and chemical properties of a medicine 
were undertaken. For the former, this included friability 
(the tendency for a tablet to break), uniformity of mass 
(weight variation amongst samples from the same batch) 
and hardness tests. Chemical tests included HPLC or 
Mass spectrometry (MS) (to assess content of the SAPI) 
or dissolution (medicine bioavailability). Of the 27 stud-
ies that reported the specific type of confirmatory tests 
they utilized, 12 conducted physical tests and also under-
took chemical testing in parallel [32–35, 37, 38, 40, 41, 
52, 72]. The remaining studies (15/27 (56%)) used chemi-
cal tests alone, either LC/MS or dissolution apparatus. 
Studies conducted in the last 5 years used confirmatory 
tests only, suggesting either that more institutions have 
now acquired HPLC and dissolution equipment or there 
is greater recognition of their importance as highly accu-
rate techniques.
Only 11/30 (37%) studies employing confirmatory tests 
stated the source of the reference standards obtained [35, 
38–42, 49, 51, 65, 76, 77] and just 14 stated the manu-
facturer of the analytical equipment [5, 32, 35–41, 49, 51, 
52, 65, 77]. In total, 7/27 (26%) studies that stated a using 
a specific type of confirmatory testing did not report 
using an international pharmacopeia [30, 50–52, 69, 76, 
77]. Reference to the use of a pharmacopeia reassures the 
reader that ratified methods for testing medicines were 
employed.
In this review, 7/39 (18%) studies did not categorize 
failing medicines, reporting them simply as having ‘failed 
the tests’ or ‘not compliant’ without providing further 
details of the criteria used [32, 34, 37, 43, 66, 73, 74]. 
The remaining studies classified failing samples as coun-
terfeit, falsified, fake, substandard, degraded and poor 
quality either alone, or in combination. In the absence of 
guidelines, no criteria for determining degraded medi-
cines were provided. There are currently no universally 
agreed definitions for poor quality medicines which may 
account for the wide array of terms used in the included 
studies [80]. Yet, standardization for definitions is impor-
tant as it enables regulatory authorities to plan appropri-
ate action to address the problem of each specific type of 
poor quality medicine.
Tolerance limits refer to the standards listed in med-
icine monographs in pharmacopeia for the SAPI of a 
medicine. Medicines failing to meet these standards 
either by having a sub-optimal amount of SAPI or 
too much, would be considered to be of poor quality. 
Of the 27 studies that stated the specific type of con-
firmatory test employed, nine did not state tolerance 
limits for the medicines and of these [29, 30, 33, 34, 
50, 51, 69, 77] eight studies still categorized the fail-
ing samples as falsified, counterfeit, poor quality and/
or substandard. The remaining study only stated that 
samples had ‘failed tests’ [34]. Without stating toler-
ance limits to compare the SAPI in the sample against 
pharmacopeia standards, these categorizations are 
unsubstantiated.
Statistical treatment of results
A thorough analysis of obtained data should include a 
statistical analysis, including p values and/or confidence 
intervals which take account of the sampling variation 
in surveys, indicating the precision of any estimates 
obtained [81]. Of the included studies, only 7/39 (18%) 
[36, 50, 51, 65, 67, 69, 72] undertook a statistical analy-
sis presenting their results with p values or confidence 
intervals.
Additionally, disparity between results from screening 
and confirmatory tests in terms of sensitivity and speci-
ficity of the screening test to classify medicines as poor 
quality, should be reported. For this study, the terms sen-
sitivity and specificity are used in their statistical sense, 
as of a measure of the performance of binary classifica-
tion tests differentiating between those medicines that 
are poor quality and good quality and how accurate these 
results are when compared to the ‘gold standard’ tests 
(HPLC and dissolution). Overall, 14/30 (47%) studies 
that stated using confirmatory tests, recorded a disparity 
with screening tests which had either overestimated or 
underestimated the quality of the samples [5, 28, 29, 32–
34, 37–42, 49, 52, 67, 70, 71, 74, 76]. However, only 7/30 
(23%) of these studies highlighted this disparity [5, 28, 34, 
42, 67, 71, 76], and a sensitivity and specificity calcula-
tion was presented in just one study [28]. Thus, although 
authors have reported findings that demonstrate a lack of 
accuracy of the screening test, they have rarely described 
the reasons for inconsistency or as a minimum, drawn 
attention to the discrepancy.
Limitations and bias
Of the included studies, 15/39 (39%) did not discuss any 
potential limitations of the study design, sampling strat-
egy or laboratory methods used [30, 32, 33, 35, 37–41, 
46–48, 50, 52, 78]. Of the remaining 24 studies, 10 pro-
vided an account of limitations specifically relevant to 
the type of screening test used, of which, five studies 
included a discussion of the disparity between results 
from screening and confirmatory tests [5, 28, 29, 34, 65, 
67, 69, 71, 74, 75].
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Overall 16/39 (41%) studies discussed a potential risk 
of bias in their studies. Of these, 15 studies mentioned 
the risk of selection bias related to either the sampling 
strategy, a small sample size or in the sample selection 
for analysis by confirmatory tests [5, 28, 29, 31, 34, 36, 
65–67, 69, 71, 72, 74, 75, 77]. The risk of operator error 
in performing a test incorrectly or misinterpreting results 
(misclassification bias) was cited by 3/16 (19%) stud-
ies [65, 66, 74]. In addition, 2/16 (13%) studies stated a 
concern of performance (observer) bias and the need to 
blind any additional operators involved in testing (or re-
testing) medicine samples [51, 67].
Dissemination of findings
Overall, 9/39 (23%) studies stated that they had shared 
their findings (or intended to do so) with either the Min-
istry of Health or the relevant NMRA [28–30, 33, 36, 67, 
69, 71, 73].
Discussion
In contrast to the extensive discourse in recent years on 
how medicine quality should be defined, much less atten-
tion has been paid to reporting of both the technologies 
used to assess medicine quality and the results obtained 
[80]. This review summarizes the current evidence on 
the reporting of findings from anti-malarial medicine 
quality surveys in LMICs that have employed screening 
technologies and provides guidance on how reporting 
could be improved for future studies. Our results high-
light the great variation in study design, survey methods 
and laboratory procedures used. The lack of standardiza-
tion hinders comparison between studies, and is a poten-
tial source of error and bias. The review reveals the need 
for procedures to be more comprehensively reported in a 
standardized manner, to more readily evaluate the accu-
racy of estimates of medicine quality obtained in surveys, 
and to compare results across studies. Medicine quality 
surveyors and researchers ought to state in detail, the 
analytical methods which they have used and provide an 
indication of the reliability of the results obtained [82]. 
Clear and thorough reporting on analytical methods and 
study findings should include the following aspects as a 
minimum; sampling strategies, specific details of screen-
ing and confirmatory test procedures, test repetition, 
blinding of operators, use of reference standards, and 
reporting on risk of bias to enable results to be inter-
preted with greater confidence.
Establishing conclusive evidence for the accuracy of 
commonly used screening tests is challenging as there is 
little information available on the precision of methods 
for detecting poor quality anti-malarials. The accuracy 
of the most frequently employed screening technique, 
the  MiniLab® (TLC test), has been questioned as it has 
previously been shown to overestimate medicine qual-
ity for anti-malarials, producing false positive results 
when samples are compared to analysis by HPLC [5, 28, 
83]. Indeed, the  MiniLab® has been described as “only 
being able to detect grossly substandard or counterfeit 
medicines” [71]. Nevertheless, cost effective screening 
technologies have a key role in providing an indication 
of medicine quality and are especially useful in settings 
where confirmatory tests are not readily available. Yet, 
medicine quality surveys that elect to solely utilize 
screening technologies should be scrutinized thoroughly 
and regulatory decisions actioned after completing verifi-
cation of suspect samples by confirmatory tests [84].
This review, has found that just under half (14/30 
(47%)) of the studies reported a discrepancy in the results 
once confirmatory testing had been carried out subse-
quent to using screening tests. However, only the WHO 
multi-country study carried out a specificity and sensi-
tivity calculation to explore the extent of the discrepancy 
[28]. There is a need to establish the precise accuracy of 
each of the screening techniques available for all medi-
cines they test, and it should be mandatory for manufac-
turers of new technologies to report the sensitivity and 
specificity of the test, determined through both feasibility 
testing in a laboratory setting and piloting in the field.
Strengths and limitations of the review
The quality assessment score used in this review has sug-
gested that reporting in anti-malarial medicine quality 
studies is not satisfactory; potentially limiting the ability 
of an NMRA to take action in the case of finding a poor 
quality medicine. However, there are two caveats to the 
criteria used. Firstly, if a study has not employed con-
firmatory tests it will inevitably be assigned a lower score 
as the study cannot fulfil 8 of the 23 criteria stipulated. 
Secondly, studies failing to provide pertinent informa-
tion on the methods used, as well as those with a limited 
study design, would both obtain a low score. Nonethe-
less, this information is essential to have confidence in 
the accuracy of the results reported. A strength of the 
scoring criteria is that they do provide a broad indication 
of the rigour of the research design and the reliability of 
the results. The wide range in scores (2–17) in this review 
indicate that there is still considerable room for improve-
ment in the reporting of medicine quality studies.
A review of the grey literature using keyword search 
terms in generic web search engines was not conducted. 
The majority of findings [36/39 studies (92%)] presented 
in this review are from academic peer-reviewed papers 
published in international journals and not from reports 
produced by NMRAs which are often the key organiza-
tions at country level conducting anti-malarial medi-
cine quality surveys. Country specific medicine quality 
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reports from national surveys conducted by NMRAs or 
similar agencies may exist but are less accessible, as they 
are either published internally or for dissemination to 
funders and operational partners and may only be pub-
lished on an ad hoc basis. The limited number of these 
types of report found in the process of the literature 
search did not meet the inclusion criteria.
Conclusions
The frequency with which medicine quality studies 
and surveys are being conducted by a diverse profile of 
organizations and academic institutions from LMICs, 
North America and parts of Europe has increased appre-
ciably. Whilst a multidisciplinary approach to the field 
of medicine quality is both required and encouraged, 
researchers involved in these studies can differ in their 
disciplinary background (pharmacy, chemistry, medicine, 
epidemiology etc.), knowledge, and experience, placing 
an increased and urgent need for convergence toward an 
agreed approach to studies and surveys [84].
This review has found much heterogeneity across the 
included studies in terms of study design and consist-
ency in reporting, which impacts on the generalizabil-
ity of survey results and further perpetuates the lack of 
information on the accuracy of the most popular screen-
ing technologies. The introduction of reporting guide-
lines, such as the CONSORT and STROBE guidelines, 
have helped to standardize the reporting of clinical tri-
als and epidemiological studies, and increased the clar-
ity and scientific rigour of study design, facilitating the 
interpretation of results and comparison between stud-
ies. In contrast, there is little guidance on the reporting 
of findings from medicine quality surveys with the sole 
exception of the MEDQUARG checklist, applied in only 
one of the studies included in this review [69]. The MED-
QUARG checklist provides guidance on sampling in 
medicine quality surveys. At country level, USP have pro-
vided guidance for conducting medicine quality surveys. 
Despite the availability of these two sets of guidelines the 
divergence in study designs limits the interpretation of 
findings and the comparison between studies.
It has also been highlighted here that the standard of 
reports is limited by a number of common weaknesses 
across studies. This includes small sample sizes (especially 
at the level of the confirmatory test), a lack of blinding 
of operators, limited results verification, and ambiguity 
in sample selection for confirmatory tests, all of which 
may bias results. A set of standardized guidelines would 
help to reduce variation and decrease the risk of bias in 
medicine quality studies. The authors propose that the 
measures for reporting the quality of a medicine qual-
ity survey in this review, should be used in conjunction 
with the MEDQUARG and USP guidelines, as a checklist 
for academics and programme managers in designing 
surveys and reporting results. This would facilitate the 
assessment of the reliability and accuracy of findings by 
national and international authorities (NMRAs, WHO, 
USP etc.), journal editors and peer reviewers.
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